Skip to main content
. 2023 Dec 6;17(24):24654–24667. doi: 10.1021/acsnano.3c03305

Figure 4.

Figure 4

Pirfenidone/m significantly enhances the effectiveness of immunotherapy. (A) Experimental treatment protocol. Created with BioRender.com. (B) Images of E0771 tumors after removal (n = 9 or 10 mice, in the group of pirfenidone/m + ICI, three mice were cured). (C) Tumor growth (n = 9 or 10 mice), (D) tumor mass (n = 9 or 10 mice), and (E) tumor elastic modulus (n = 9 or 10 mice, N = 2 images field per mouse) measured with SWE of E0771 tumors treated with pirfenidone/m and anti-CTLA4/anti-PD-1 antibodies. (F) Representative immunofluorescence images of nuclear marker (blue), CD31 endothelial marker (red), and αSMA pericyte marker (green) immunostaining of 4T1 breast tumors treated as indicated. White scale bar indicates 0.5 mm. (G) Quantification of pericyte coverage fraction determined by the colocalization of CD31 and αSMA. (H) Quantification of the CD31 area fraction following immunostaining with an anti-CD31 endothelial cell marker. Data are presented as mean ± SE. Statistical analyses were performed by using for (C) mixed-effects analysis with multiple comparisons Tukey test, for (D, G, H) ordinary one-way ANOVA with multiple comparisons Dunnett test, and for (E) two-way ANOVA with multiple comparisons Dunnett test.